CUE
Cue Biopharma, Inc.
There isn't enough reported data to score CUE yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
CUE Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Unavailable |
CUE's revenue is currently strong, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
CUE PE Valuation
CUE has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
CUE Forward outlook
There aren't enough analyst estimates for CUE to show an outlook.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
CUE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$25.82 | -$9.92 |
| Q1 2026 | -$4.38 | +$14.82 |
| Q4 2025 | -$8.40 | +$13.20 |
| Q3 2025 | -$12.90 | +$14.40 |
| Q2 2025 | -$15.90 | +$13.50 |
| Q1 2025 | -$19.20 | +$12.90 |
| Q4 2024 | -$21.60 | +$11.70 |
| Q3 2024 | -$27.30 | +$8.40 |
CUE has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
CUE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $7.9M | +167% |
| Q1 2026 | $5.7M | +1251% |
| Q4 2025 | $21.9M | +1292% |
| Q3 2025 | $2.1M | -36% |
| Q2 2025 | $3M | +11% |
| Q1 2025 | $421K | -75% |
| Q4 2024 | $1.6M | -13% |
| Q3 2024 | $3.3M | +59% |
CUE's revenue is growing: $8M last quarter, up 167% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -1113% | -821 points |
| Q1 2026 | -94% | +2827 points |
| Q4 2025 | 9% | +620 points |
| Q3 2025 | -353% | -89 points |
| Q2 2025 | -292% | +98 points |
| Q1 2025 | -2921% | -2184 points |
| Q4 2024 | -611% | +148 points |
| Q3 2024 | -264% | +280 points |
CUE's operating margin was −1113% last quarter, down 821 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over CUE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over CUE on profitability, with a higher operating margin.
CUE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$29M | -$25.6M |
| Q1 2026 | -$11.1M | -$2.7M |
| Q4 2025 | -$1.1M | +$8M |
| Q3 2025 | -$9M | -$1.5M |
| Q2 2025 | -$3.4M | +$6.6M |
| Q1 2025 | -$8.3M | +$1.5M |
| Q4 2024 | -$9M | +$1.9M |
| Q3 2024 | -$7.5M | +$273K |
CUE has burned cash in almost every quarter: −$50M over the past year, against −$28M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over CUE on cash generation, producing positive trailing cash flow while its opponent burns cash.
CUE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +32% | +1.5M shares |
| 1 year | +99% | +3.2M shares |
| 3 years | +325% | +4.8M shares |
| 5 years | +509% | +5.3M shares |
| Available history | +747% | +5.6M shares |
CUE has 6M diluted shares, up 99% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | $127 |
| Q3 2022 | $9,000 |
| Q2 2022 | — |
| Q1 2022 | $191,000 |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over CUE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
CUE Net Leverage
CUE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
CUE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.8 | Neutral |
| Stochastic | 12.2 | Oversold |
CUE's weekly RSI is 44 (neutral) and its Stochastic is 12 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
CUE PE vs Healthcare Sector
CUE has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
CUE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $22.1 | 21% below |
| 20 week MA | $26.9 | 35% below |
| 50 week MA | $20.1 | 13% below |
| 100 week MA | $23.3 | 25% below |
| 200 week MA | $46.7 | 63% below |
CUE is in a downtrend: it's below all five of its weekly moving averages, and 63% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
CUE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $524.1 | $393.6 | -25% |
| 2021 | $393.6 | $373.2 | -5.2% |
| 2022 | $373.2 | $82.5 | -78% |
| 2023 | $82.5 | $79.2 | -4% |
| 2024 | $79.2 | $31.2 | -61% |
| 2025 | $31.2 | $9.74 | -69% |
| 2026 YTD | $9.74 | $17.5 | +80% |
CUE has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.